Welcome to our dedicated page for Neogenomics SEC filings (Ticker: NEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to NeoGenomics, Inc. (NASDAQ: NEO) SEC filings, offering a regulatory view of the company’s activities as a public cancer diagnostics business. NeoGenomics is a Nevada corporation with common stock listed on The Nasdaq Stock Market LLC under the symbol NEO, as disclosed in its Form 8-K filings.
Investors can review current reports on Form 8-K, which NeoGenomics uses to furnish quarterly financial results, preliminary revenue updates, and information about board and executive changes. Recent 8-K filings have reported results for fiscal quarters, described financial metrics such as revenue and operating expenses, and documented director appointments and resignations.
Through this page, users can also monitor quarterly and annual reports (Forms 10-Q and 10-K when available) that typically include detailed discussions of the company’s oncology diagnostics operations, risk factors, and financial statements. These filings complement the company’s news releases describing clinical test volumes, next-generation sequencing contributions, and research and development spending.
For those tracking governance and corporate actions, the SEC filings detail matters such as board composition and compensation arrangements for directors, as reflected in 8-K disclosures about board changes. Filings related to financial results often reference non-GAAP measures like Adjusted EBITDA and Adjusted Gross Profit Margin, with reconciliations and definitions included in the attached press releases.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings, highlight notable changes from prior periods, and make it easier to locate items related to revenue trends, operating performance, and governance updates. Real-time updates from EDGAR help ensure that new NeoGenomics filings, including any future Forms 10-K, 10-Q, or Form 4 insider transaction reports, are quickly reflected and summarized for NEO investors and researchers.
NeoGenomics Director Marjorie C. Green received new equity compensation grants on June 19, 2025, consisting of:
- Stock Options: Granted 16,019 options to buy common stock at an exercise price of $6.95 per share. These options will become exercisable on June 1, 2026, and expire on June 19, 2035.
- Restricted Stock Units (RSUs): Awarded 22,964 RSUs that will vest on June 1, 2026. Once vested, these RSUs convert to common stock with no expiration date.
This Form 4 filing represents standard director compensation equity grants. The combined awards suggest continued commitment to aligning director interests with shareholders through long-term equity incentives. All securities are held directly by the reporting person.
NeoGenomics has filed a Form 3 (Initial Statement of Beneficial Ownership) announcing the appointment of Marjorie C. Green as a Director of the company, effective June 19, 2025. The filing discloses that:
- Green currently owns no securities or derivative securities of NeoGenomics
- She serves as a Director but holds no other positions (such as Officer or 10% Owner)
- The filing was submitted individually, not as part of a group
- The document was signed by Ali Olivo as Attorney-in-Fact on June 24, 2025
This Form 3 filing is a standard regulatory requirement for new company insiders under Section 16(a) of the Securities Exchange Act of 1934, establishing their initial ownership position upon assuming their role.
NeoGenomics has announced a significant board expansion and appointment in a Form 8-K filing. The company's Board of Directors has increased its size from nine to ten members with the appointment of Marjorie C. Green as a new director, effective June 19, 2025.
Key details of the appointment include:
- Ms. Green will serve until the 2026 annual meeting of stockholders or until resignation/removal
- She will receive compensation aligned with the company's existing independent director compensation program as disclosed in the 2025 proxy statement
- The appointment was publicly announced via press release on June 24, 2025
The filing, signed by EVP and General Counsel Alicia C. Olivo, includes standard regulatory disclosures and confirms that NeoGenomics is not classified as an emerging growth company. The company trades on the Nasdaq Stock Market under the symbol NEO.